Bridgeway Capital Management’s Elicio Therapeutics ELTX Stock Holding History

Bridgeway Capital Management’s Portfolio ELTX Stock Details ELTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-12,500	Closed	-$62.9K	–	1228
2024 Q3	$62.9K	Hold	12,500	–	–	﹤0.01%	1199
2024 Q2	$51.4K	Hold	12,500	–	–	﹤0.01%	1215
2024 Q1	$95K	Hold	12,500	–	–	﹤0.01%	1212
2023 Q4	$104K	Hold	12,500	–	–	﹤0.01%	1232
2023 Q3	$106K	Hold	12,500	–	–	﹤0.01%	1222
2023 Q2	$119K	Sell	12,500 -5,000	-29%	-$45.9K	﹤0.01%	1230
2023 Q1	$102K	Hold	17,500	–	–	﹤0.01%	1236
2022 Q4	$142K	Hold	17,500	–	–	﹤0.01%	1158
2022 Q3	$161K	Buy	17,500 +10,000	+133%	+$104K	﹤0.01%	1177
2022 Q2	$86K	Sell	7,500 -5,000	-40%	-$79.9K	﹤0.01%	1244
2022 Q1	$265K	Buy	+12,500	New	+$282K	0.01%	1113

Other funds holding ELTX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

MHC

Meyer Handelman Company Rye Brook, New York $3.53B AUM 30.49% 1-Year Est. Return

CIBC Private Wealth Group Atlanta, Georgia $59.2B AUM 20.62% 1-Year Est. Return

SPIA

Steward Partners Investment Advisory New York $19.6B AUM 29.84% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Bridgeway Capital Management's ELTX Position: Q4 2024 in Review

Bridgeway Capital Management sold out of Elicio Therapeutics (ELTX) in Q4 2024, closing a stake of 12,500 shares — an estimated $62.9K sold.

Bridgeway Capital Management first reported a position in ELTX in Q1 2022 and held it in 11 quarters. The position peaked at $265K in Q1 2022. 17 funds tracked by Wall St. Rank hold ELTX as of Q4 2024.

Bridgeway Capital Management reported no remaining Elicio Therapeutics position as of Q4 2024 after selling out during the quarter.
Bridgeway Capital Management sold 12,500 Elicio Therapeutics shares in Q4 2024, an estimated $62.9K.
Bridgeway Capital Management first reported a position in Elicio Therapeutics in Q1 2022 and held it in 11 quarters.
Bridgeway Capital Management's Elicio Therapeutics position peaked at $265K in Q1 2022.
17 funds tracked by Wall St. Rank held Elicio Therapeutics as of Q4 2024.

Based on Bridgeway Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.